[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606305":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":42,"locations":52,"responsibleParty":68,"collaborators":70,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":10,"enrollmentInfo":82,"targetDuration":10,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Recruited patient",null,"Glioblastoma patient with indication for neurosurgery",[13],"Other: samples",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"samples","A 50 ml blood sample will be taken from the patient before the operation, and two 0.3 cm3 tumor samples will be taken during the operation from the resected tumor.",[9],[20,23,26,28,31,34,36,38,40],{"name":21,"affiliation":5,"role":22},"Julien ENGELHARDT, Dr","PRINCIPAL_INVESTIGATOR",{"name":24,"affiliation":5,"role":25},"Mathieu LARROQUETTE, Dr","STUDY_CHAIR",{"name":27,"affiliation":5,"role":25},"Guillaume CHOTARD, Dr",{"name":29,"affiliation":30,"role":25},"Lionel COUZI, Pr","Bordeaux university Hospital, Bordeaux University",{"name":32,"affiliation":33,"role":25},"Andreas BIKFALVI, Pr","University of Bordeaux",{"name":35,"affiliation":5,"role":25},"Charles DUPIN, Dr",{"name":37,"affiliation":30,"role":25},"Véronique VENDRELY, Pr",{"name":39,"affiliation":33,"role":25},"Julie DECHANET-MERVILLE, Dr",{"name":41,"affiliation":33,"role":25},"Thomas DAUBON, Dr",[43,48],{"name":21,"role":44,"phone":45,"phoneExt":46,"email":47},"CONTACT","05 56 79 55 77","+33","julien.engelhardt@chu-bordeaux.fr",{"name":49,"role":44,"phone":50,"phoneExt":46,"email":51},"Olivier BRANCHARD","05 57 82 06 97","olivier.branchard@chu-bordeaux.fr",[53],{"facility":54,"status":55,"city":56,"state":10,"zip":10,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"CHU de Bordeaux","RECRUITING","Bordeaux","France","FR",{"type":60,"coordinates":61},"Point",[62,63],-0.58046,44.84124,{"lat":63,"lon":62},[66],{"name":67,"role":44,"phone":45,"phoneExt":46,"email":47},"Julien ENGELHARDT, MD",{"type":69,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[71],{"name":33,"class":6},"100606305","a-study-to-better-understand-the-biological-and-molecular-mechanisms-involved-in-glioblastoma-recurrence-and-progression-100606305",false,"NCT07173829","A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression","A Prospective Study to Better Understand the Molecular, Immune and Metabolic Mechanisms Involved in Glioblastoma Recurrence and Progression, in the Aim to Identify New Therapeutic Targets and to Improve Current Therapies","BORDEAUX-GLIO","Inclusion Criteria:\n\n* Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery\n* Planned surgical tumor resection,\n* No objection to participate in research\n* Signed genetic consent\n\nExclusion Criteria:\n\n* Patients under guardianship, curatorship or protective supervision\n* Taking immunosuppressants\n* Pregnant or breast-feeding women\n* Patients deprived of their liberty by judicial or administrative decision, or under psychiatric care","ALL","18 Years",{"count":83,"type":84},45,"ESTIMATED","OBSERVATIONAL","BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center.",[88],"Glioblastoma",[90,91,92,93,94,95,96,97,98,99],"Glioblastoma progression","Glioblastoma recurrence","Metabolism","Lactate","Metabolomic","Transcriptomic","Radiation therapy","Radiosensitizer","Immunotherapy","γδ T lymphocytes","2026-08-04",{"date":102,"type":103},"2026-08-07","ACTUAL",{"date":105,"type":103},"2025-10-22",{"date":107,"type":84},"2031-10",{"name":5,"class":6},1]